Shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) have been given an average rating of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $17.20.
Several equities research analysts have recently weighed in on the company. Stifel Nicolaus decreased their price objective on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a report on Monday, May 11th. Mizuho reduced their price target on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. HC Wainwright decreased their price target on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, Weiss Ratings downgraded shares of Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th.
Get Our Latest Stock Report on Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc. Common Stock Stock Performance
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). The firm had revenue of $11.71 million for the quarter. Senseonics Holdings, Inc. Common Stock had a negative return on equity of 129.97% and a negative net margin of 213.87%. As a group, analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.38 earnings per share for the current year.
Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock
In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder bought 22,686 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was acquired at an average price of $5.56 per share, for a total transaction of $126,134.16. Following the completion of the purchase, the director owned 144,635 shares of the company’s stock, valued at approximately $804,170.60. This represents a 18.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.70% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of SENS. Ausdal Financial Partners Inc. increased its holdings in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the third quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after purchasing an additional 35,000 shares during the period. GSK plc purchased a new position in Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at $60,000. Townsend Asset Management Corp NC ADV acquired a new position in Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at $60,000. Kestra Advisory Services LLC acquired a new position in Senseonics Holdings, Inc. Common Stock in the 1st quarter valued at $68,000. Finally, Sanctuary Advisors LLC purchased a new position in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth $71,000. 12.36% of the stock is currently owned by hedge funds and other institutional investors.
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.
Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.
Further Reading
- Five stocks we like better than Senseonics Holdings, Inc. Common Stock
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Senseonics Holdings Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
